Skip to content
Trial Eligibility
Menu

MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer

NCT04599218

This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This research study is designed to determine if targeted Magnetic Resonance Imaging (MRI) Ultrasound (US) fusion biopsy is better than the standard of care ultrasound guided biopsy alone in diagnosing subjects with clinically significant prostate cancer with MRI visible lesions. This study will consist of comparing the standard of care (ultrasound guided prostate biopsy) with the protocol biopsy which consists of an ultrasound guided prostate biopsy and a MRI/US fusion tracked prostate biopsy.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Prostate Disease
  • Elevated Prostate Specific Antigen
  • Family History of Prostate Cancer
  • Positive Digital Rectal Exam
  • Prostate Cancer

Eligibility basics and study details

Study type
Interventional
Phase
Not applicable
Ages
18 years and older
Sex
Male
Healthy volunteers
Not accepted
Sponsor
Ardeshir Rastinehad
Last updated on ClinicalTrials.gov
November 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New York · 3

  • The Smith Institute for Urology · Lake Success, NY
  • Manhattan Eye, Ear, and Throat Hospital (MEETH) · New York, NY
  • The Smith Institute for Urology at Lenox Hill · New York, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.